ADRX
SinkerADARx Pharmaceuticals, Inc. · Healthcare · United States · $1.9B cap · $6.6M/day traded
$14.20 -4.8% · close 13 Nov · scored 14 Nov
Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.
As of 14 Nov 2026, the MoatMap Score for ADARx Pharmaceuticals, Inc. (ADRX) is 9/100, ranked against 25,000+ stocks in 38 markets (Quality 35, Value 22, Momentum 23, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT ADARX PHARMACEUTICALS, INC.
Read
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|
| Income and shares | ||||||
| Revenue | — | 3.4M | 6.1M | 6.2M | 39.9M | 240.0% |
| Net margin | n/m | -2119.1% | — | — | — | — |
| EPS | -0.62 | -0.97 | -1.16 | -2.03 | -1.45 | — |
| Share count | 102.2M | 102.2M | 110.7M | — | — | — |
| Balance sheet | ||||||
| Debt | 4.3M | 7.7M | 6.9M | — | — | — |
| Equity | -137.1M | -202.3M | — | — | — | — |
| Debt/equity | n/m | n/m | — | — | — | — |
| Cash flow | ||||||
| Op. cash flow | -48.6M | 262.3M | -88.3M | — | — | — |
| Cash flow margin | n/m | 7604.8% | -1441.5% | — | — | — |
| Investing CF | 39.5M | -209.9M | — | — | — | — |
| Financing CF | 0.2M | 97.0K | — | — | — | — |
Not enough steady price history for a read yet.
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend: It is near its 52-week high and above its 200-day average.
- No clear trend: None of the above: no recent deep fall and no steady climb.
- No read yet (this stock): Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ADRX are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| ADRX | ADARx Pharmaceuticals, Inc.(you) | $1.9B | 9 |
| MLYS | Mineralys Therapeutics, Inc. | $1.8B | 6 |
| STOK | Stoke Therapeutics, Inc. | $1.6B | 9 |
| IMNM | Immunome, Inc. | $2.1B | 11 |
| VERA | Vera Therapeutics, Inc. | $2.0B | 6 |
| RARE | Ultragenyx Pharmaceutical Inc. | $1.5B | 10 |
| NTLA | Intellia Therapeutics, Inc. | $1.6B | 7 |
| LYCA | Lycia Therapeutics, Inc. | $1.6B | 7 |
| KLRA | Kailera Therapeutics, Inc. | $1.7B | 13 |
| GENB | Generate Biomedicines, Inc. | $1.6B | 5 |
Peer medians: ROE -29.9% · P/E 26.6x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.